StockNews.AI
TARS
StockNews.AI
2 days

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

1. Tarsus will webcast its Q4 and full-year 2024 financial results update. The call includes a corporate update. 2. The webcast is scheduled for Feb 25, 2025 at 5:00 AM PT/8:00 AM ET. It is open to investors. 3. The release highlights FDA approval of XDEMVY for Demodex blepharitis. The pipeline includes TP-04 and TP-05 candidates. 4. A recorded version will be available for 90 days post-call. The update may clarify progress in eye care and infectious disease.

3 mins saved
Full Article

FAQ

Why Neutral?

This is a routine earnings webcast and corporate update. Similar past earnings announcements typically have a neutral immediate price impact unless results deviate significantly from expectations.

How important is it?

While the webcast is key for investor updates, routine financial disclosures are often already priced in. The event's significance depends on whether the reported results exceed or miss market expectations.

Why Short Term?

Earnings updates often cause short-term volatility as investors react to financial performance. Historical examples show that routine disclosures have immediate but transient impacts.

Related Companies

February 20, 2025 17:00 ET  | Source: Tarsus Pharmaceuticals, Inc IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. Media Contact:Adrienne KempSr. Director, Corporate Communications(949) 922-0801AKemp@tarsusrx.com Investor Contact:David NakasoneHead of Investor Relations(949) 620-3223DNakasone@tarsusrx.com

Related News